Jan 1, 1975

Analysis of skin grafts across the MSA-barrier in mice pretreated with sera from specifically or syngeeically grafted donors

Folia Biologica
V ViklickýJ Skajster


Prolonged survival of weakly incompatible skin allografts in mice (across the barrier presented by the MSA) can be induced by pretreating the recipients not only with a specific anti-MSA serum (obtained on day 5 after a single MSA-incompatible skin graft) but also be means of control serum obtained in a similar way from the recipients of fully compatible (syngeneic) skin grafts. Administration of serum from non-grafted mice had no effect on graft survival. The similar biological effect of both sera had a counterpart in their similar content and spectrum of glycosaminoglycans. Also in the skin grafts themselves, the course of both qualitative and quantitative changes of GAG in the early postgrafting period was in the allogeneic and syngeneic situation similar. The possible role of these substances in the serum and at the site of grafting and their effect on the outcome of the allograft response are discussed.

  • References
  • Citations


  • We're still populating references for this paper, please check back later.
  • References
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Graft Survival
Graft Vs Host Reaction
Phosphoglycerate Dehydrogenase Activity
Antibody Formation
PHGDH wt Allele
Transplantation, Homologous

About this Paper

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.